Biocartics
Oncology point-of-care diagnostics ($100M IPO in 2015)

 

IPO Filed in 2015

Biocartis is an innovative commercial stage molecular testing company providing next generation solutions to researchers in oncology and infectious disease. Our global headquarters are in Mechelen, Belgium with a U.S. office located in Jersey City, New Jersey.

Our proprietary Idylla™ platform is a fully automated, real time system which offers highly-reliable molecular information from both tissue and plasma in virtually any lab setting. This is the first ever fully automated molecular testing system with a growing menu focused on oncology.

Globally, we have a presence in 70 countries and there are over 500 Idylla™ systems in place. We’re also working with a number of key industry partners as we develop a rapidly expanding test menu to meet and address growing needs in the oncology sector. These partnerships include an agreement with Amgen to validate our RAS tests for future use as a CDx for Vectibix®, which is the first fully human monoclonal anti-EGFR antibody approved by the FDA for the treatment of mCRC. In addition to our direct sales channels, the Idylla™ platform is also available in the U.S. through our national distribution partner Thermo Fisher Scientific.

As a company, our goal is to make molecular testing convenient and affordable while providing direct access to molecular testing, anywhere and anytime.

http://us.biocartis.com/